Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1019-2026

Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300 Recall

Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300

FDA recall Class II

Ongoing

FDA lists this Class II recall for Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1019-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Dec 5, 2025
FDA report date
Jan 14, 2026
Quantity in commerce
211 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300

Affected model & UDI checker

Search the exact identifiers published for Z-1019-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
410300Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300Check source noticeNot specified
Not specifiedRevogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300Check source notice00840733102349
FDA code information

UDI-DI: 00840733102349; Lot Numbers: 410300U195, 410300U196, 410300U197, 410300U201

View the original FDA recall notice

Why was this product recalled?

The affected lots show a decline in performance over time, which may lead to false-negative results.

What actions did Meridian Bioscience Inc take?

An "URGENT MEDICAL DEVICE CORRECTION" dated 12/1/25 was sent to customers. Required Actions: " Identify and segregate any remaining inventory of impacted product lots and suspend further use. " Destroy remaining inventory of impacted product lot in accordance with state, local, and/or federal regulations. o Contact Technical Service for replacement product. " Review previously obtained results from Revogene C. difficile listed Lots numbers. Any negative results obtained should be re-evaluated in conjunction with presented clinical findings to determine if retesting is required. " Complete and return the CONFIRMATION OF NOTIFICATION Form. Complete this form even if there is no remaining inventory. Actions to Be Taken By Meridian Bioscience, Inc.: Meridian Bioscience, Inc. will replace any unused inventory and provide support for any necessary retesting, including replacement test materials as needed. Contact Information: For any question regarding this notification please call Meridian Bioscience Technical Service at 1-800-343-3858, or email at [email protected].

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology